All the news Showing 10 of 46 articles from: Access to medicines & diagnosticsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources More work and lower drug prices are needed to eliminate hepatitis C worldwide Liz Highleyman / 27 November 2017 Eliminating hepatitis C virus (HCV) as a global public health concern is feasible, but to do this more people need to be tested and treated and prices of direct-acting antivirals ... Global progress towards hepatitis C elimination still blocked by cost of treatment, lack of diagnosis Keith Alcorn / 02 November 2017 Nine countries – Australia, Brazil, Egypt, Georgia, Germany, Iceland, Japan, the Netherlands and Qatar – are on course to eliminate hepatitis C by 2030, according to data released at the World Hepatitis ... Hepatitis C halved in Spanish people living with HIV in one year due to treatment Keith Alcorn / 27 October 2017 Spain is making dramatic progress towards eliminating hepatitis C in people living with HIV because of widespread use of direct-acting antivirals, Juan Berenguer of Hospital Gregorio Marañón, Madrid, reported on Friday at the ... Restrictions on free DAA access in many European countries contrary to guidelines and undermine HCV elimination targets, say researchers Michael Carter / 16 October 2017 The restrictions which many European countries impose on free/reimbursed access to hepatitis C virus (HCV) direct-acting antivirals (DAAs) are contrary to guidelines and undermine the World Health Organization (WHO) goal ... High prices of DAAs mean there's been little progress towards achieving WHO target of eliminating HCV by 2030 Michael Carter / 13 September 2017 Only a handful of countries are on course to achieve the World Health Organization (WHO) target of eliminating hepatitis C virus (HCV) as a major public health concern by 2030, ... The availability of direct-acting antivirals is reducing disparities in the uptake of hepatitis C treatment Roger Pebody / 30 August 2017 An analysis from British Columbia, Canada shows that older people, individuals with HIV co-infection, people with cirrhosis and – to some extent – people who inject drugs have been significantly ... Countries and donors should aim for new $90-$90-$90 target on HIV, hepatitis, TB drug prices, study shows Keith Alcorn / 27 July 2017 HIV, hepatitis B and C and tuberculosis (TB) can each be treated for less than $90 a year where generic drugs can be made available, Dzintars Gotham of Imperial College, London, reported ... Hepatitis C treatment is effective and feasible in Africa Liz Highleyman / 25 July 2017 Treatment for hepatitis C in sub-Saharan Africa can produce cure rates as high as those seen in industrialised countries, with high adherence and minimal side-effects, according to a presentation yesterday at the ... Generic hepatitis C drugs continue to produce high cure rates Keith Alcorn / 24 April 2017 Treatment with generic versions of direct-acting antiviral drugs continues to produce similar cure rates to those reported in clinical trials, Dr James Freeman reported last week at the International Liver ... European HCV treatment access survey shows big variations in eligibility Keith Alcorn / 20 April 2017 England, Malta, Slovakia, Hungary and Croatia have the tightest restrictions on who can receive direct-acting antiviral (DAA) treatment for hepatitis C, while France, Ireland, Portugal, Germany, Poland and the Netherlands are the least ... ← Prev12345Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Access to medicines & diagnostics Hepatitis C elimination Models of care Finance, funding & health economics National policy European policy International policy Activism and civil society Pharmaceutical industry Social issues Conference news Email bulletin archive